Latest News and Press Releases

Primary and all major secondary efficacy endpoints were highly statistically significant Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy...

– Financial guidance and clinical timelines for rilonacept, mavrilimumab, vixarelimab and KPL-404 remain intact amid COVID-19 pandemic –– Mavrilimumab treatment protocol in COVID-19 pneumonia and...

HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

- Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without pericarditis recurrence - -...

HAMILTON, Bermuda, May 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

– First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis– Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mavrilimumab, respectively–...

- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in...

- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial,...

MORGANTOWN, PA--(Marketwired - Oct 2, 2013) - With its extensive new line of Rhapsody carriage style garage doors, Artisan Custom Doorworks has successfully blended luxury and...

DALLAS, TX--(Marketwired - Jul 31, 2013) -  New digital audio research from Parks Associates predicts the number of music streaming subscribers worldwide will reach 15 million by 2017, and the...